Sanofi's subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. Sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85. The company has a market capitalization of $13.45 billion, a P/E ratio of 32.05, a P/E/G ratio of 0.61 and a beta of ...

Leading companies such as BioMarin Pharmaceuticals Inc. and Sanofi S.A. are at the forefront of the Aldurazyme market. Their commitment to research, innovation, and the development of cutting-edge ...

How Do Unusual Items Influence Profit? To properly understand BioMarin Pharmaceutical's profit results, we need to consider the US$86m expense attributed to unusual items. It's never great to see ...

Collegium Pharmaceutical, Inc. is headquartered in Stoughton, MA, which is just outside of Boston. The company's focused has been on pain management products, but a more recent acquisition got it ...